Treatment outcomes of depression: The pharmacogenomic research network antidepressant medication pharmacogenomic study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 3, 2014, Pages 313-317

  Mrazek, David A ^a   Biernacka, Joanna M ^a   McAlpine, Donald E ^a   Benitez, Joachim ^b   Karpyak, Victor M ^a   Williams, Mark D ^a   Hall Flavin, Daniel K ^a   Netzel, Pamela J ^a   Passov, Victoria ^c   Rohland, Barbara M ^a   Shinozaki, Gen ^d   Hoberg, Astrid A ^a   Snyder, Karen A ^a   Drews, Maureen S ^a   Skime, Michelle K ^a   Sagen, Jessica A ^a   Schaid, Daniel J ^a   Weinshilboum, Richard ^e   Katzelnick, David J ^a  

^a MAYO CLINIC   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

antidepressants; depression; mood disorders; pharmacotherapy; treatment

Indexed keywords

CITALOPRAM; ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FOLLOW UP; HAMILTON SCALE; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHOLOGIC TEST; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY CLINICIAN RATED; REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOGENETICS; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84900504784     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000099     Document Type: Article

References (15)

1. National Guideline C. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Available at: http://www.guidelines.gov/ content.aspx?id=24158. Accessed January 31, 2013.
2. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
3. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303:47-53.
4. Hicks P, Hicks XP. Depression severity and effect of antidepressant medications. JAMA. 2010;303:1598.
5. Parker G. Antidepressants on trial: how valid is the evidence? Brit J Psychiatry. 2009;194:1-3.
6. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
7. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493-501.
8. Mrazek DA, Biernacka JM, O'Kane DJ, et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics. 2011;21:1-9.
9. Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:341-351.
10. First M, Spitzer R, Williams J, et al. Structured Clinical Interview for DSM-IV (SCID). Washington, DC: American Psychiatric Association; 1995
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
12. Wisniewski SR, Stegman D, Trivedi M, et al. Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). J Psychiatr Res. 2004;38:241-248.
13. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-142.
14. Wisniewski SR, Rush AJ, Balasubramani GK, et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12:71-79.
15. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573-583.